This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DBV Technologies : DBV Technologies Announces Topline Financial Results For First Three Months 2014

BAGNEUX, France, April 15, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new reference in the treatment of allergy, announced today its topline financial results, as well as its net cash position, for first three months 2014.

Topline Financial Results for first three months 2014

For the first three months 2014, total revenues reached €1,277,349, up from €796,101 for the same period in 2013. This sensible evolution primarily results from an increase in Research Tax Credit amounting to €1,227,140 over the period, compared to €794,903 a year earlier. This progression stems from the intense R&D activities conducted by DBV. The Company did not sell any Diallertest® to its commercial partner over the period.

Net cash position at 31 March 2014

As of 31 March 2014, DBV's cash position amounted to €34.6 million, compared with €39.4 million three months earlier. The cash burn therefore amounted to €4.8 million for the first three months 2014.

David Schilansky, Chief Financial Officer, commented: "Six months away from phase II VIPES' results, a key step in the Company's development, and soon with 6 clinical programs running simultaneously, keeping control of our cash burn remains an important challenge for DBV. The cash burn for the first quarter was in line with our expectations, and illustrates our attention to contain the pace of our spending before Viaskin Peanut enters into phase III, as planned in 2015."

DBV Technologies will announce its financial results for the first six months on 28 July 2014.

About DBV Technologies:

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people, constituting a major unmet medical need. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanuts, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure The product's clinically proven safety profile enables the application of effective desensitization techniques in the most severe forms of the allergy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,811.90 -116.30 -0.65%
S&P 500 2,082.71 -6.75 -0.32%
NASDAQ 4,922.6920 -16.6350 -0.34%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs